At the last check on Friday, NeuroOne Medical Technologies Corporation’s (NASDAQ:NMTC) stock was down -$0.28, moving down -16.01 percent to $1.47. The average number of shares traded per day over the past five days has been 1,864,286 shares. 3 times new highs have been achieved over the past 5 days, with a $0.6508 gain in that time frame. In the last twenty days, the average volume was 545,472, while in the previous 50 days, it was 240,537.
Since last month, NMTC stock rose 15.13%. Shares of the company fell to $0.8000 on 11/18/22, the lowest level in the past month. A 52-week high of $3.18 was reached on 02/11/22 after having rallying from a 52-week low of $0.51. Since the beginning of this year, NMTC’s stock price has dropped by -9.79% or -$0.4400, and marked a new high 7 times. However, the stock has declined by -53.78% since its 52-week high.
Do You Own These 7 Inflation-Survival Stocks?
Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.
Click here to get your free copy of the report
NMTC stock investors should be aware that NeuroOne Medical Technologies Corporation (NMTC) stock had its last reported insider trading activity 163 days ago on Jun 15. McClurg Ronald W., the Chief Financial Officer of the company, purchased of 10,000 shares for $1.02 on Jun 15. It resulted in a $10,219 investment by the insider. McClurg Ronald W. added 14,000 shares at an average price of $1.06 on Jun 10. The insider now owns 57,000 shares following the transaction. On May 24, Chief Financial Officer McClurg Ronald W. bought 10,500 shares at $0.98 apiece. The transaction was valued at $10,291.
The stock’s beta is 0.47. Besides these, the trailing price-to-sales (P/S) ratio of 143.76, the price-to-book (PB) ratio of 2.65.
In the three months ended June 29, NeuroOne Medical Technologies Corporation’s quick ratio stood at 12.90, while its current ratio was 13.40, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is -38.00% percent. Based on annual data, NMTC earned $33000.0 in gross profit and brought in $0.24 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -154.80%. Return on equity (ROE) for the past 12 months was -97.50%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. NMTC’s revenue fell -33.33% during the quarter, while net income inched up to $30000.0. While analysts expected NeuroOne Medical Technologies Corporation to report -$0.22 quarterly earnings, the actual figure was -$0.17 per share, beating the consensus estimate by 22.70%. During the quarter, the company generated -$2.73 million in EBITDA. The liabilities of NeuroOne Medical Technologies Corporation were 0.95 million at the end of its most recent quarter ended June 29, and its total debt was $0.23 million. The value of shareholders’ equity is $16.21 million.
This quick technical analysis looks at NeuroOne Medical Technologies Corporation’s (NMTC) price momentum. With a historical volatility rate of 252.34%, the RSI 9-day stood at 65.06% on 23 November.
With respect to its five-day moving average, the current NeuroOne Medical Technologies Corporation price is up by +76.64% percent or $0.6508. At present, NMTC shares trade +26.05% above its 20-day simple moving average and +48.51% percent above its 100-day simple moving average. However, the stock is currently trading approximately -29.91% below its SMA50 and -40.94% below its SMA200.
Stochastic coefficient K was 84.97% and Stochastic coefficient D was 84.87%, while ATR was 0.2270. Given the Stochastic reading of 68.63% for the 14-day period, the RSI (14) reading has been calculated as 59.97%. As of today, the MACD Oscillator reading stands at 0.4042, while the 14-day reading stands at 0.4539.